Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics

Simple item page
dc.contributor.authorOlmos, PR
dc.contributor.authorHodgson, MI
dc.contributor.authorMaiz, A
dc.contributor.authorManrique, M
dc.contributor.authorDe Valdes, MD
dc.contributor.authorFoncea, R
dc.contributor.authorAcosta, AM
dc.contributor.authorEmmerich, MV
dc.contributor.authorVelasco, S
dc.date.accessioned2024-01-10T13:51:09Z
dc.date.available2024-01-10T13:51:09Z
dc.date.issued2006
dc.description.abstractBackground: After a study of ICA prevalence among relatives of Type-1 diabetics (DMI) in Santiago, Chile, parents of those who tested positive asked us to go on forward with an intervention study.
dc.description.abstractMethods: We had screened 1021 relatives, of which 30 had shown ICA >= 20 JDF units (2.9%). Among the 26/30 who participated in the intervention study, the baseline screening showed normal glucose tolerance in all, and the first-phase insulin response (FPIR) was normal in 24/26 individuals, which were randomized into Nicotinamide (n = 12; oral Nicotinamide, 1200 mg m(-2) day(-1)) and Placebo (n = 12) groups. The FPIRs and ICAs were monitored yearly. Compliance was monitored by urine Nicotinamide.
dc.description.abstractResults: The 1.5, 3.0 and 5-year life-table estimates of keeping the FPIR >= 10th centile were, for Nicotinamide group 100% in all time points, and for Placebo these were 90.0% (c.i. = 100-71.4), 72.0% (c.i. = 100-37.1) and 0.0% (c.i. = 0.0-0.0) (p = 0.0091). The 5-year life-table estimates of remaining diabetes-free were 100% for Nicotinamide and 62.5% for Placebo (p = 0.0483). No adverse effects were observed.
dc.description.abstractConclusions: Oral Nicotinamide protected beta-cell function and prevented clinical disease in ICA-positive first-degree relatives of type-1 diabetes. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
dc.fechaingreso.objetodigital2024-04-09
dc.format.extent14 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.diabres.2005.07.009
dc.identifier.issn0168-8227
dc.identifier.pubmedidMEDLINE:16233932
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2005.07.009
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79581
dc.identifier.wosidWOS:000236292500014
dc.information.autorucMedicina;Olmos P;S/I;98949
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final333
dc.pagina.inicio320
dc.publisherELSEVIER IRELAND LTD
dc.revistaDIABETES RESEARCH AND CLINICAL PRACTICE
dc.rightsacceso restringido
dc.subjecttype-1 diabetes mellitus
dc.subjectnicotinamide
dc.subjectprevention
dc.subjectISLET-CELL ANTIBODIES
dc.subjectINTERVENTION TRIAL ENDIT
dc.subjectINTRAVENOUS GLUCOSE
dc.subjectFOLLOW-UP
dc.subjectT-CELLS
dc.subjectCHILDREN
dc.subjectMELLITUS
dc.subjectPHASE
dc.subjectPROGRESSION
dc.subjectPREDICTION
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleNicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics
dc.typeartículo
dc.volumen71
sipa.codpersvinculados98949
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics.pdf
Size:
3.09 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas